PLAINVILLE, Mass.—Bruder Healthcare, a Hilco Vision Company, announced that it has entered into an exclusive distribution agreement with Santen S.A. to market Eyeleve MGD, previously marketed in the United States as Retaine MGD. The preservative-free ophthalmic emulsion, set to launch in early 2025, provides moisture, lubrication and protection for moderate to severe evaporative dry eye (EDE), Bruder Healthcare stated. With 80 percent of dry eye patients suffering from EDE, the company said that Eyeleve MGD will serve a crucial need of patients and practitioners alike.

The formulation uses a preservative-free oil-in-water cationic emulsion technology. This technology delivers ingredients through electrostatic attraction between positively charged droplets and the negatively charged ocular surface, relieving dry eye symptoms by moisturizing, lubricating and protecting the eyes, the announcement said.

“We are thrilled to introduce Eyeleve MGD to our portfolio of dry eye treatments. Adding Eyeleve MGD strengthens our product line and better equips eyecare professionals to provide solutions for patients on the road back to healthy eyes," said Brent Jones, global head of Vision Care Solutions at Hilco Vision. 

Bruder Healthcare noted the hypotonicity of the emulsion in Eyeleve MGD adds moisture by lowering the salt concentration of tears, while the lipid component lubricates and protects the eye surface. As a result, the company added, this unique combination of ingredients ensures that patients experience relief from dry eye symptoms, improving their overall eye health and comfort. 

“This preservative-free drop not only addresses the physiological challenges of dry eye but also enhances patients' quality of life, particularly in activities like prolonged computer use, underscoring its role as a promising option in the battle against dry eye syndrome,” said Paul Karpecki, OD, co-author of a study published in Clinical Ophthalmology. He added that study data demonstrated a therapeutic effect of the formulation on the signs and symptoms of dry eye after two weeks of treatment. In addition, study participants experienced an immediate-onset transient improvement in tear film stability.  

For more about Eyeleve MGD, visit www.eyeleve.com. For more information about Bruder Healthcare, visit www.bruderpro.com (for doctors) or www.bruder.com (for consumers).